Kelun Pharma's Unit Gets Nod for Antigen Drug's Second Indication

MT Newswires Live2025-03-11

China's drug administrator approved adding a second indication for sac-TMT, the antibody-drug conjugate targeting human trophoblast surface antigen 2 of Sichuan Kelun Pharmaceutical's (SHE:002422) unit, Sichuan Kelun Botai Biopharmaceutical, according to a Shenzhen Stock Exchange disclosure on Tuesday.

The drug's second indication states that it can be used for treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer, the pharmaceutical company said.

The drug is also used for breast cancer, gastric cancer, gynecological tumors and other advanced solid tumors.

The company's shares rose 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518319751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-11 12:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518319751","market":"fut","top_or_hot":-1,"title":"Kelun Pharma's Unit Gets Nod for Antigen Drug's Second Indication","media":"MT Newswires Live","content":"<html><body><p> China's drug administrator approved adding a second indication for sac-TMT, the antibody-drug conjugate targeting human trophoblast surface antigen 2 of Sichuan Kelun Pharmaceutical's (SHE:002422) unit, Sichuan Kelun Botai Biopharmaceutical, according to a Shenzhen Stock Exchange disclosure on Tuesday.</p><p>The drug's second indication states that it can be used for treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer, the pharmaceutical company said.</p><p>The drug is also used for breast cancer, gastric cancer, gynecological tumors and other advanced solid tumors.</p><p>The company's shares rose 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun Pharma's Unit Gets Nod for Antigen Drug's Second Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun Pharma's Unit Gets Nod for Antigen Drug's Second Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-11 12:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's drug administrator approved adding a second indication for sac-TMT, the antibody-drug conjugate targeting human trophoblast surface antigen 2 of Sichuan Kelun Pharmaceutical's (SHE:002422) unit, Sichuan Kelun Botai Biopharmaceutical, according to a Shenzhen Stock Exchange disclosure on Tuesday.</p><p>The drug's second indication states that it can be used for treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer, the pharmaceutical company said.</p><p>The drug is also used for breast cancer, gastric cancer, gynecological tumors and other advanced solid tumors.</p><p>The company's shares rose 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2518319751","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518319751","pubTimestamp":1741666327,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's drug administrator approved adding a second indication for sac-TMT, the antibody-drug conjugate targeting human trophoblast surface antigen 2 of Sichuan Kelun Pharmaceutical's  unit, Sichuan Kelun Botai Biopharmaceutical, according to a Shenzhen Stock Exchange disclosure on Tuesday.The drug's second indication states that it can be used for treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer, the pharmaceutical company said.The drug is also used for breast cancer, gastric cancer, gynecological tumors and other advanced solid tumors.The company's shares rose 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0060":"抗癌","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","002422":"科伦药业","BK0239":"医药制造"},"translate_title":"科伦药业旗下抗原药物第二个适应症获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002422":0.6},"content_text":"China's drug administrator approved adding a second indication for sac-TMT, the antibody-drug conjugate targeting human trophoblast surface antigen 2 of Sichuan Kelun Pharmaceutical's (SHE:002422) unit, Sichuan Kelun Botai Biopharmaceutical, according to a Shenzhen Stock Exchange disclosure on Tuesday.The drug's second indication states that it can be used for treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer, the pharmaceutical company said.The drug is also used for breast cancer, gastric cancer, gynecological tumors and other advanced solid tumors.The company's shares rose 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518319751","isCrawlerRequest":true}